Guangdong Second Provincial General Hospital clinical trials
Guangdong Second Provincial General Hospital is the lead sponsor of 8 current clinical trials in our China register. 1 is recruiting patients now. The most common phase is Phase 2. The drugs named most often in its trials are Azacitidine, Cytarabine and Etoposide. The most-studied condition is Relapsed or Refractory Multiple Myeloma.
ClinicalTrials.gov trials by status
Trials by phase
Clinical trials sponsored by Guangdong Second Provincial General Hospital
8 on ClinicalTrials.gov| Study | Phase | Status | Start | Registers |
|---|---|---|---|---|
|
Luspatercept for CIA in AML
NCT07663864 · ClinicalTrials.gov ↗ · Chemotherapy-inducing Anemia
|
Phase 1/2 | Recruiting | 2026-06 | China |
|
To Assess Safety, Tolerability, and Efficacy of Anti-GPRC5D-CD19-CAR-T in Relapsed/Refractory Multiple Myeloma
NCT06298266 · ClinicalTrials.gov ↗ · Relapsed or Refractory Multiple Myeloma
|
Early Phase 1 | Not yet open | 2024-03 | China |
|
Selective Intra-Arterial Hypothermia After Endovascular Treatment for Acute Basilar Artery Occlusion
NCT07896655 · ClinicalTrials.gov ↗ · Acute Ischemic Stroke, Basilar Artery Occlusion
|
Not applicable | Not yet open | 2026-12 | China |
|
Thiotepa + TBI + Fludarabine + Etoposide for Allo-HSCT in Patients With R/R or High-risk Acute Leukemia
NCT07920796 · ClinicalTrials.gov ↗ · Acute Leukemia, High Risk, Acute Leukemia Refractory, Acute Leukemia, Relapsed
|
Phase 2 | By invitation | 2026-06 | China |
|
Homoharringtonine, Lisaftoclax, and Azacitidine for AML After Venetoclax-Based Therapy Failure
NCT07813390 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia (AML)
|
Phase 2 | By invitation | 2026-09 | China |
|
VEN+IDAC vs IDAC in AML
NCT07537257 · ClinicalTrials.gov ↗ · AML (Acute Myelogenous Leukemia)
Drugs: Cytarabine, Ventoclax |
Phase 2/3 | By invitation | 2026-04 | China |
|
HVA in the Treatment of Mixed-Phenotype Acute Leukemia(MPAL).
NCT07517510 · ClinicalTrials.gov ↗ · Newly Diagnosed Mixed Phenotype Acute Leukemia (MPAL)
|
Phase 2 | By invitation | 2026-04 | China |
|
Chidamide in HR-AML
NCT07822789 · ClinicalTrials.gov ↗ · Acute Myeloid Leukemia, Maintenance Therapy
|
Observational | Active, closed | 2026-07 | China |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.
Drugs in Guangdong Second Provincial General Hospital trials
8 compoundsDrugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.
Conditions in Guangdong Second Provincial General Hospital trials
12 conditionsBy trial register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in China | 8 | 1 |
A trial with sites in more than one country appears in each of those registers.
Other sponsors in Relapsed or Refractory Multiple Myeloma
| Sponsor | Trials |
|---|---|
| Qilu Pharmaceutical | 3 |
| Celgene | 1 |
| Jiangsu Simcere Pharmaceutical | 1 |
| Hangzhou Sumgen Biotech | 1 |
| Shandong New Time Pharmaceutical | 1 |
Sponsors with the most current trials registered for this condition.
Questions about Guangdong Second Provincial General Hospital trials
How many clinical trials does Guangdong Second Provincial General Hospital sponsor?
Guangdong Second Provincial General Hospital is the lead sponsor of 8 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 11 November 2026. Completed and withdrawn studies are not counted.
Are Guangdong Second Provincial General Hospital trials recruiting?
Yes. 1 of its 8 ClinicalTrials.gov trials is recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Which drugs is Guangdong Second Provincial General Hospital testing?
Its current trials name 8 drugs and biologicals as interventions. The most frequent are Azacitidine (1), Cytarabine (1), Etoposide (1), Fludarabine (1) and Homoharringtonine (1). The number in brackets is how many of its trials name each drug.
Where does this information come from?
Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.
How this page is built
Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, lead sponsor, phase, overall status, start date, conditions and intervention names
- EU Clinical Trials Information System (CTIS) ↗ EU trial numbers, titles, sponsor, phase, status, therapeutic area and member-state countries
This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 11 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.